Sermorelin and the GHRP family: two doors into the same GH pulse

Plain-language summary

Sermorelin and the GHRP trio (hexarelin, GHRP-2, GHRP-6) both push the pituitary to release more growth hormone, but through two different receptors. Sermorelin copies GHRH and works through the GHRH receptor, the body's own upstream trigger. Hexarelin, GHRP-2, and GHRP-6 copy ghrelin instead, working through the ghrelin receptor (GHS-R1a), a separate pathway that also drives hunger. Human pharmacology studies going back to the 1980s and 1990s confirm all four reliably raise GH, and that combining a GHRH-class peptide with a GHRP produces a synergistic release bigger than either alone. What none of that establishes is whether raising GH this way changes muscle, fat, or recovery outcomes in a healthy adult.

What was studied

Human pharmacokinetic and pharmacodynamic studies measuring GH (and in some cases IGF-1, cortisol, and prolactin) responses to single and combined doses. GHRP-2 additionally has a real regulatory approval in Japan as a diagnostic GH-stimulation test (pralmorelin). Several studies specifically tested GHRH plus a GHRP together to measure synergy rather than either compound alone.

Key takeaways

• GHRH-class (sermorelin) and ghrelin-receptor-class (hexarelin, GHRP-2, GHRP-6) secretagogues use different receptors, and human studies from the 1990s show combining the two classes produces GH release well above the arithmetic sum of either alone.
• GHRP-2 is the one compound in this group with an actual drug approval, marketed in Japan as pralmorelin for single-dose diagnostic GH testing, not for repeated self-dosing.
• GHRP-6, the oldest of the group (1984), reliably produces the strongest appetite stimulation of the four, a direct and well-documented consequence of activating the ghrelin receptor's hunger-signaling side.
• Cortisol and prolactin rise alongside GH with the ghrelin-receptor peptides, more so than with GHRH-class sermorelin, a hormonal side effect profile that shows up consistently across the human pharmacology literature.

Limitations & what we don't know

• Almost all of the underlying human data measures hormone levels over hours to days, not body composition, strength, or recovery outcomes over months.
• Most of the foundational studies are small, decades-old pharmacology trials, not modern randomized outcome trials.
• GHRP-2's only real regulatory approval is for a single diagnostic dose, which says nothing about the safety of the repeated self-administered protocols common in research-chemical use.
• None of the three GHRPs is approved for any use in the US or EU; sermorelin's approved branded form (Geref) was discontinued in 2008 and what's sold today is compounded.

1. 1.

   Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men

   1992 · human

   Sermorelin's active fragment restored GH and IGF-1 toward youthful levels in elderly men.

2. 2.

   Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man

   1994 · human

   Established hexarelin as one of the most potent human GH secretagogues tested, across several routes.

3. 3.

   Growth hormone-releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men

   2005 · human

   Confirmed GHRP-2's appetite-stimulating effect in a controlled human feeding study.

4. 4.

   On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone

   1984 · animal

   The founding paper describing GHRP-6, the ancestor compound of this entire peptide family.

5. 5.

   Growth hormone (GH) responses to the combined administration of GH-releasing hormone plus GH-releasing peptide 6 in adults with GH deficiency

   1995 · human

   Direct human test of the GHRH-plus-GHRP-6 combination, documenting a synergistic GH response beyond either compound alone.